Key Highlights
- Zoetis shares plummeted 20% to $88.94 Thursday, marking the worst single-day performance across the S&P 500 index
- First-quarter earnings of $1.53 per share fell short of the $1.60 analyst projection; sales of $2.26B underperformed the $2.3B forecast
- Management slashed annual EPS projections to a range of $6.85–$7.00 from the previous $7.00–$7.10 guidance
- Company leadership attributed weakness to growing consumer price consciousness and declining veterinary clinic traffic
- Analysts at Stifel noted the underlying performance was “worse than it seems” after accounting for a $100M one-time revenue benefit from fiscal calendar adjustments
Shares of Zoetis (ZTS) experienced a dramatic 20% decline to $88.94 during Thursday’s trading session, positioning it as the poorest performer within the S&P 500 index. Data from Dow Jones Market Data indicates the stock is tracking toward its weakest closing price in more than seven years, with year-to-date losses now reaching 29%.
The sharp decline followed the animal healthcare company’s announcement of first-quarter financial results that disappointed investors on both earnings and revenue metrics.
First-quarter profit reached $1.53 per share, representing growth from $1.48 in the prior-year period but falling short of the $1.60 Wall Street projection. Sales advanced 3% year-over-year to $2.26 billion, missing the $2.3 billion analyst forecast compiled by FactSet.
Chief Executive Kristin Peck acknowledged the quarter unfolded in a more challenging landscape than management had anticipated. Pet owners have become more budget-conscious, resulting in reduced veterinary visits and diminished demand for higher-priced offerings.
Domestic revenue declined approximately 8% year-over-year to $1.1 billion. Sales of companion animal products within the U.S. market fell roughly 11%, pressured by softer consumer demand and intensifying competitive dynamics.
Overseas Operations Provided Limited Support
Revenue from international markets climbed 17% year-over-year to $1.1 billion, supported by a 10% increase in companion animal product sales. The company’s parasiticide product line served as a primary growth catalyst.
Nevertheless, the international figure incorporated approximately $100 million in revenue accelerated from a change in fiscal reporting alignment. The organization removed a one-month reporting delay for its international divisions, artificially inflating Q1 overseas results in a non-recurring manner.
Wall Street Analysts Express Deeper Concerns
Stifel’s Jonathan Block and his research colleagues characterized the Q1 results as actually “worse than it seems.” After adjusting for the $100 million realignment advantage, organic operational revenue expansion came in substantially below market expectations.
Block’s team highlighted “notable weakness” within the pet healthcare segment as a significant area of concern.
In response, Zoetis revised downward its 2026 full-year projections. The company now anticipates adjusted EPS in the range of $6.85 to $7.00, reduced from the prior guidance of $7.00 to $7.10. Street consensus had been estimating $7.03.
Annual revenue guidance was similarly trimmed to between $9.68 billion and $9.96 billion, compared to the earlier range of $9.825 billion to $10.025 billion. Analyst consensus stood at $9.89 billion.
Peck stated the organization is implementing “decisive action to sharpen commercial execution, unlock revenue, and continue to drive disciplined cost management.”
The stock’s 20% single-session plunge has pushed ZTS to price levels last observed in early 2019.
Adjusted earnings of $1.53 represented approximately 9% year-over-year expansion, yet still underperformed consensus projections by $0.09.
Thursday’s dramatic move brings the full-year decline to 29%, representing a challenging period for an equity previously regarded as a reliable growth performer within the healthcare sector.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
